TS-075261 — Problem Hemolysis, the process by which the red blood cell membrane ruptures, releasing hemoglobin (Hb), is typically managed in mammalian organisms by intrinsic proteins such as hemopexin (Hpx) and haptoglobin (Hp). However, their concentrations in plasma are very limited, so, in conditions with s…

TS-075260 — Problem Type 2 diabetes and related metabolic disorders affect hundreds of millions of patients and are frequently accompanied by chronic inflammation, which accelerates disease progression and complications. Existing antidiabetic therapies often fail to adequately address inflammatory pathways and…

TS-075258 — PROBLEM Chronic heart failure following myocardial infarction (MI) afflicts ~6.7 million US adults and is driven by maladaptive immune activation, particularly persistent activation and proliferation of CD4+ T cells. Existing anti-inflammatory and immunomodulatory approaches have largely failed to …

TS-075255 — Problem The limited regenerative capacity of adult CNS neurons upon transection results in chronic neurological disability. There is an urgent need to develop novel therapies that facilitate CNS axon regeneration and ultimately restore lost neurological functions. Solution Applications Advan…

TS-075254 — Problem Cardiomyopathy weakens the heart muscle and impairs its ability to pump blood effectively, often leading to heart failure or sudden cardiac death. While doxorubicin remains an essential component of many cancer regimens, its use is limited by the risk of causing lethal cardiomyopathy. A maj…

TS-075247 — PROBLEM Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ damage, affecting women at a 9:1 rate as compared to men. The etiology of SLE is complex and incompletely understood; however, the susceptibility of women during the years in which estrogen levels ar…

TS-075245 — Problem Although cyclin dependent kinase 9 (CDK9) is a promising drug target, traditional small-molecule inhibitors face challenges due to CDK9's structural similarities with other kinases, leading to off-target effects and limited efficacy Solution Applications Advantages Seeking opp…

TS-075243 — Problem Central nervous system (CNS) injury can result in permanent neurological disability and vision loss. There is a dire need to develop novel therapies that overcome barriers to repair within the CNS and promote neuron survival and axon regeneration. Solution Applicat…

TS-075242 — THE PROBLEM Although immune checkpoint blockade (ICB) has emerged as promising cancer immunotherapy, many tumors fail to respond to ICB. This failed response is often driven by the activation of TGF-β1 in the tumor microenvironment (TME), which induces regulatory T cells and inhibits the funct…

TS-075241 — Problem Cardiovascular diseases (CVDs) such as heart failure, myocardial infarction, and cardiomyopathies remain leading causes of death worldwide. Notably, heart failure is the only major cardiovascular condition still increasing in prevalence. Current treatments primarily consist in managing the …

TS-075240 — Problem Dedifferentiated liposarcomas (DDLPS) are aggressive soft tissue sarcomas with limited effective treatment options and a dismal prognosis. Current therapies often fail due to tumor resistance, poor specificity, and toxicity. The aggressive clinical behavior of LPS and its resistance to chem…

TS-075239 — Papaverine is an FDA-approved potent inhibitor of mitochondrial complex I. Papaverine’s mitochondrial complex I inhibition has been shown to be responsible for increased oxygenation and enhanced radiation response. However, papaverine is also a phosphodiesterase 10A (PDE10A) inhibitor with pot…

TS-075238 — Problem Low titer group O whole blood (LTOWB) is the gold standard used by the US military to treat blood loss. However, there is a limited supply with ex vivo storage and shelf-life limitations. There is no whole blood substitute on the market when LTOWB is not available. Solution Dr. Andre Palmer and team have developed several whole blood substitute formulations to mimic the 3 main functions of whole blood: 1) oxygen transport (provided by hemoglobin-based oxygen carrier [HBOC]); 2) clotting (provided by tranexamic acid); and 3) volume replacement (provided by a plasma substitute). The HBOC consists of T-state polymerized human hemoglobin (PolyhHb). The clotting agent consists of tranexamic acid (TXA). The volume replacement solution consists of polymerized human serum albumin (PolyHSA). Additional additives include high molecular weight polyethylene glycol as a drag reducing agent, and dexamethasone as an anti-inflammatory agent. Applications Prehospital and austere environments Used by EMS and military for early resuscitation before hospital arrival Hospital trauma protocols Used for first-line transfusion in exsanguinating patients Advantages Mimics the three major functions of whole blood without the risk of blood type incompatibility and disease transmission Extended shelf life versus whole blood Scalable production Seeking opportunities for out-licensing and collaboration

TS-075234 — PROBLEM Dysregulation of the cardiac ryanodine receptor (RyR2) leads to abnormal Ca2+ release, a central driver of serious cardiovascular diseases including congestive heart failure (CHF), catecholaminergic polymorphic ventricular tachycardia (CPVT), arrhythmogenic right ventricular dysplasia (ARVD…

TS-075233 — Problem Transducin β-like protein 1 (TBL1) has emerged as a promising therapeutic target in oncology, due to its central role in regulating multiple oncogenic signaling pathways. The challenge is how to develop a selective and effective inhibitor of TBL1 with high efficacy and limited side-eff…

TS-075232 — Problem Breast cancer (BC) is the most commonly diagnosed malignancy and the second leading cause of cancer-related death among women in the United States. Within its subtypes, triple-negative breast cancer (TNBC) carries the highest mortality, driven in large part by a lack of effective targeted t…

TS-075231 — Problem Despite recent progress in cancer therapy, acquired resistance to existing cancer drugs reduces therapeutic efficacy. There is a strong need for a therapy with a novel mode of action to overcome drug resistance, and to improve therapeutic efficacy whether used alone or in combination therap…

TS-075191 — PROBLEM Cancer immunotherapies (e.g. ICB, CAR-T cells, and conventional bispecific T cell engagers) have transformed treatment of hematological and solid malignancies; however, their impact is limited by several factors including insufficient durability of therapeutic activity, tumor heterogeneity,…

TS-075188 — Problem The liver sinusoidal clearance system (LSCS) is responsible for eliminating the majority of circulating macromolecular waste, inflammatory mediators, toxins, and therapeutic agents. Excessive hepatic clearance limits the efficacy of therapies, including chemotherapies and vaccines. In contr…

TS-075186 — PROBLEM Exhausted CD8 T cells significantly limit the effectiveness of immunotherapies and cell therapies in cancer and chronic viral infections. Persistent antigen exposure drives durable epigenetic reprogramming that locks T cells into a dysfunctional state, silencing effector and memory-associat…

TS-075185 — Problem The lipolysis-stimulated lipoprotein receptor (LSR) is a promising target for cancer therapy. LSR is overexpressed in many tumor tissues with metastatic signatures such as breast, gastric, and endometrial cancer. LSR expression levels may serve as prognostic indicators and help stratify pat…

TS-075183 — Problem Current eligibility biomarkers for Immune checkpoint inhibitors (ICIs) poorly predict patient’s response. Drug clearance, both at baseline and over time, is a stronger predictor of ICI effectiveness, however the current non-linear mixed effects modeling (NLME) approach for estimating …

TS-075182 — PROBLEM Prostate cancer (PCa) and urothelial cancers (UC) are among the most commonly diagnosed malignancies in aging adults, and their management is characterized by prolonged, costly, and invasive surveillance pathways. Both diseases exhibit marked molecular heterogeneity that drives prognosis, t…

TS-075181 — PROBLEM Metabolic diseases and peripheral neuropathies represent a major public health burden in the United States, and the risks increase as we age. Metabolic diseases, including diabetes and obesity, and peripheral neuropathy (PN) affect approximately 25-45% and 10-20% of U.S. adults aged 50-70 r…

TS-075179 — Problem Mitochondria is a promising target for cancer treatment. However, current strategies to specifically and effectively destroy cancer mitochondria in vivo are limited. Solution Applications Competitive Advantages Seeking Opportunities for Licensing and collaboration

TS-075178 — Problem Over 30,000 Americans are diagnosed every year with multiple myeloma (MM), a disease of clonal plasma cells which accumulate in the bone marrow. Despite several treatment options, MM is still incurable, and patients inevitably relapse and develop toxicities and functional decline. Novel the…

TS-075175 — Problem Idiopathic pulmonary fibrosis (IPF) is a chronic disease where activated fibroblasts mediate the abnormal accumulation of extracellular matrix (ECM) in the lung interstitial space, leading to progressive impairment of pulmonary function. Current IPF therapies are associated with significant…

TS-075174 — Problem IL-2 and its receptor IL-2R are known to play multiple roles in shaping the immune response, including both immune activation and tolerance. Treatments activating effector cells against tumors are undermined by an autoinhibitory loop caused by endogenous IL-2 secreted from activated Teffs. …

TS-075167 — PROBLEM CAR T-cell therapy against CD19 has become the standard of care for relapsed/refractory B-cell non-Hodgkin lymphoma (NHL), the most common kind of lymphoma. Recent studies have identified clinical risk factors for prediction of CAR T therapy failure; however, these risk factors are inconsis…

TS-075165 — Problem Neuroendocrine tumors (NETs) are often metastatic at diagnosis, thus limiting surgical options. Chemotherapies offer limited efficacy and high toxicity. Meningiomas, though usually benign, are the most common intracranial tumors. Both NETs and meningiomas overexpress SSTR2, making it a prom…

TS-075164 — The Problem Treatments for inherited retinal diseases are currently limited. Gene therapy has emerged as a strong treatment option. However, difficulties have arisen with these gene therapies. It has been found that an intrathecal injection of adenoassociated viral (AAV) gene therapy vector does no…

TS-075163 — THE PROBLEM High-grade gliomas, including glioblastoma multiforme (GBM), are the most common primary central nervous system tumors with a high recurrence rate and extremely poor overall survival with a 5-year survival rate of approximately 5%. Despite success of CAR-T therapy in treating blood canc…

TS-075162 — THE PROBLEM Despite advances in classical Hodgkin’s Lymphoma (cHL) treatment, significant challenges persist with up to 40% of patients relapsing after first-line therapy and 50% after autologous stem cell transplant (aSCT). Current therapies like brentuximab vedotin and checkpoint inhibitors…

TS-075161 — Problem Acute and chronic pulmonary inflammation conditions, such as acute respiratory distress syndrome (ARDS), acute lung injury (ALI) and asthma, remain a significant healthcare challenge with high mortality rates, long-term morbidity and a substantial economic burden due to prolonged hospital s…

TS-075160 — Problem Peripheral neuropathy (PN) results in loss of innervation by the peripheral nerves in tissues such as skin, muscle, heart and subcutaneous white adipose tissue (scWAT). It is mostly associated with diabetes, obesity, aging, and chemotherapy. Affecting 10-20% of U.S. adults aged 50-70, PN is…

TS-075141 — THE PROBLEM Current MS treatments typically employ broad immunosuppression rather than targeting specific pathways, resulting in significant side effects and inadequate responses in many patients. The IL-6/STAT3 pathway is critical for balancing inflammatory T effector cells and protective regulato…

TS-074218 — This HIV-focused technology introduces a novel strategy for engaging conserved viral biology that is not directly addressed by existing antiretroviral classes. By expanding the range of actionable HIV mechanisms, the approach creates new opportunities for therapeutic discovery, combination strategies, and next‑generation intervention concepts. The technology is designed to complement current HIV treatment paradigms while supporting diversification of long‑term antiviral pipelines.

TS-073895 — The Need In the rapidly evolving field of biotechnology and pharmaceuticals, there is a critical need for efficient delivery mechanisms to transport therapeutic agents directly into cells. Cell-penetrating peptides (CPPs) initially were considered a potential solution. Short sequences of amino acid…

TS-072004 — Empower your pipeline with a versatile platform for efficient, customizable biomolecule transport.

TS-071830 — Unlocking plant-powered solutions to deliver effective inflammation relief and enhance disease outcomes.

TS-068425 — Functionalization of scFvs with cyclic peptide linkers

TS-066912 — Targeted humanized mAbs and ADCs for cancer treatment

TS-066878 — New and more effective treatments for corneal injuries.

TS-066773 — The Need Cardiomyopathy, a disease of the heart muscle, poses significant public health challenges due to its diverse causes, symptoms, and potential complications, including heart failure and arrhythmias. With cardiomyopathy often induced by drugs, such as anthracyclines used in chemotherapy, ther…

TS-066751 — The Need In the rapidly evolving field of biotechnology and pharmaceuticals, there is a critical need for efficient delivery mechanisms to transport therapeutic agents directly into cells. Cell-penetrating peptides (CPPs) initially were considered a potential solution. Short sequences of amino acid…

TS-066750 — The ongoing COVID-19 pandemic, caused by the SARS-CoV-2 virus, has significantly impacted global health and economies. Despite vaccine efforts, issues such as vaccine hesitancy, delays in distribution, and emerging variants have highlighted the need for effective therapeutic interventions. These i…

TS-066191 — , T2019-164, T2020-002, T2020-159, T2020-222: Using rhMG53 to treat conditions involving damaged tissue, including corneal repair, hepatic tissue injury, inflammatory bowel disease, and other tissue injury.

TS-066100 — Research tool to transfect cells ex vivo using electroporation through electrospun core-shell fibers for research applications

TS-066052 — Novel T-cells expressing the IL-2a receptor to enhance cancer cell targeting.

TS-066051 — Novel antibodies targeting IL-2 with the ability to inhibit IL-2 signaling through IL-2 Rαβg to a greater extent than through IL-2 Rβg.